{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:22:23Z","timestamp":1790659343835,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2024.e24655","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T10:27:29Z","timestamp":1705400849000},"page":"e24655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["ACE inhibitors and their interaction with systems and molecules involved in metabolism"],"prefix":"10.1016","volume":"10","author":[{"given":"Diana L.","family":"Silva-Velasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz G.","family":"Cervantes-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-8344","authenticated-orcid":false,"given":"Alicia","family":"S\u00e1nchez-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e24655_bib1","article-title":"Physiology, Renin Angiotensin System. [Updated 2023 Mar 12]. In: StatPearls [Internet]. Treasure Island (FL)","author":"Fountain","year":"2023","journal-title":"StatPearls Publishing"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24655_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25020295","article-title":"Considerations for docking of selective angiotensin-converting enzyme inhibitors","volume":"25","author":"Caballero","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24655_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jcp.10294","article-title":"Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition","volume":"196","author":"Henriksen","year":"2003","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.heliyon.2024.e24655_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.05.020","article-title":"The renin-angiotensin-aldosterone system and its therapeutic targets","volume":"186","author":"Mirabito Colafella","year":"2019","journal-title":"Exp. Eye Res."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24655_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin-angiotensin system in cardiovascular disease","volume":"17","author":"Paz Ocaranza","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.heliyon.2024.e24655_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fmed.2019.00107","article-title":"Alamandine and its receptor MrgD pair up to join the protective arm of the renin-angiotensin system","volume":"6","author":"Schleifenbaum","year":"2019","journal-title":"Front. Med."},{"key":"10.1016\/j.heliyon.2024.e24655_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fendo.2014.00113","article-title":"Clinical relevance of local Renin Angiotensin systems","volume":"5","author":"Campbell","year":"2014","journal-title":"Front. Endocrinol."},{"issue":"3991","key":"10.1016\/j.heliyon.2024.e24655_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1126\/science.173.3991.64","article-title":"Angiotensin-forming enzyme in brain tissue","volume":"173","author":"Ganten","year":"1971","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24655_bib9","article-title":"An update on the tissue renin angiotensin system and its role in physiology and pathology","volume":"6","author":"Nehme","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24655_bib10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","article-title":"Renin-angiotensin system revisited","volume":"264","author":"Fyhrquist","year":"2008","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24655_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/08037050310001057","article-title":"Angiotensin AT1\/AT2 receptors: regulation, signalling and function","volume":"12","author":"Kaschina","year":"2003","journal-title":"Blood Pres."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24655_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/HYPERTENSIONAHA.121.17041","article-title":"Selective inhibition of the C-domain of ACE (Angiotensin-Converting enzyme) combined with inhibition of NEP (neprilysin): a potential new therapy for hypertension","volume":"78","author":"Alves-Lopes","year":"2021","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e24655_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198500301-00002","article-title":"History of the development of inhibitors of angiotensin I conversion","volume":"30","author":"Ferreira","year":"1985","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2024.e24655_bib14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0006-2952(62)90119-3","article-title":"An enzyme in human blood plasma that inactivates bradykinin and kallidins","volume":"11","author":"Erdos","year":"1962","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e24655_bib15","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/0006-2952(63)90094-7","article-title":"Inhibition in vivo of the enzymatic inactivation of bradykinin and kallidin","volume":"12","author":"Erdos","year":"1963","journal-title":"Biochem. Pharmacol."},{"issue":"25","key":"10.1016\/j.heliyon.2024.e24655_bib16","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1021\/bi00644a014","article-title":"Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids","volume":"16","author":"Cushman","year":"1977","journal-title":"Biochemistry"},{"issue":"4288","key":"10.1016\/j.heliyon.2024.e24655_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1126\/science.191908","article-title":"Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents","volume":"196","author":"Ondetti","year":"1977","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24655_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00003088-200241030-00005","article-title":"Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update","volume":"41","author":"Song","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.heliyon.2024.e24655_bib19","series-title":"Captopril, in StatPearls","author":"Marte","year":"2022"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24655_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.dsx.2020.03.016","article-title":"Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24655_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.5471","article-title":"Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)","volume":"251","author":"Bourgonje","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.heliyon.2024.e24655_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.576745","article-title":"ACE2\/ADAM17\/TMPRSS2 interplay may Be the main risk factor for COVID-19","volume":"11","author":"Zipeto","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e24655_bib23","series-title":"StatPearls","article-title":"Angiotensin converting enzyme inhibitors (ACEI)","author":"Herman","year":"2022"},{"issue":"27","key":"10.1016\/j.heliyon.2024.e24655_bib24","first-page":"2129","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J, 2016"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24655_bib25","first-page":"e137","article-title":"ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart failure society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation, 2017"},{"key":"10.1016\/j.heliyon.2024.e24655_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.resp.2020.103613","article-title":"Angiotensin converting enzyme inhibition improves cerebrovascular control during exercise in male rats with heart failure","volume":"286","author":"Butenas","year":"2021","journal-title":"Respir. Physiol. Neurobiol."},{"issue":"25","key":"10.1016\/j.heliyon.2024.e24655_bib27","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM198006193022501","article-title":"Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure","volume":"302","author":"Dzau","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e24655_bib28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/000331979704800806","article-title":"Effect of enalapril maleate on cerebral blood flow in patients with chronic heart failure","volume":"48","author":"Kamishirado","year":"1997","journal-title":"Angiology"},{"issue":"5B","key":"10.1016\/j.heliyon.2024.e24655_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9343(84)90892-1","article-title":"Cerebral blood flow in patients with congestive heart failure treated with captopril","volume":"76","author":"Paulson","year":"1984","journal-title":"Am. J. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e24655_bib30","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1179\/1743132814Y.0000000335","article-title":"Association between angiotensin converting enzyme gene insertion\/deletion polymorphism and ischemic stroke in north Indian population: a case-control study and meta-analysis","volume":"36","author":"Kumar","year":"2014","journal-title":"Neurol. Res."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e24655_bib31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/00207454.2017.1412962","article-title":"The D allele of the angiotensin-converting enzyme (ACE) insertion\/deletion (I\/D) polymorphism is associated with worse functional outcome of ischaemic stroke","volume":"128","author":"Malueka","year":"2018","journal-title":"Int. J. Neurosci."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24655_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065700","article-title":"Single nucleotide polymorphisms of the angiotensin-converting enzyme (ACE) gene are associated with essential hypertension and increased ACE enzyme levels in Mexican individuals","volume":"8","author":"Martinez-Rodriguez","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e24655_bib33","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1097\/01.hjh.0000746472.35950.67","article-title":"ANGIOTENSIN-CONVERTING enzyme inhibitors and angiotensin receptor blockers in stroke prevention: a systematic review and meta-analysis involving 297,451 patients","volume":"39","author":"Alosaimi","year":"2021","journal-title":"J. Hypertens."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e24655_bib34","doi-asserted-by":"crossref","first-page":"E269","DOI":"10.1503\/cmaj.081657","article-title":"Prophylaxis of migraine headache","volume":"182","author":"Pringsheim","year":"2010","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"issue":"7277","key":"10.1016\/j.heliyon.2024.e24655_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/bmj.322.7277.19","article-title":"Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study","volume":"322","author":"Schrader","year":"2001","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24655_bib36","first-page":"72","article-title":"Efficacy of enalapril in migraine prophylaxis: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Sonbolestan","year":"2013","journal-title":"Int. J. Prev. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24655_bib37","first-page":"475","article-title":"[Captopril versus placebo in the prevention of hemicrania without aura. A randomized double-blind study]","volume":"141","author":"Paterna","year":"1992","journal-title":"Clin. Ter."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24655_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13041-020-00580-x","article-title":"Cortical potentiation induced by calcitonin gene-related peptide (CGRP) in the insular cortex of adult mice","volume":"13","author":"Liu","year":"2020","journal-title":"Mol. Brain"},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e24655_bib39","first-page":"15","article-title":"Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone","volume":"88","author":"Luscher","year":"1993","journal-title":"Basic Res. Cardiol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24655_bib40","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.hjh.0000220419.86149.11","article-title":"Involvement of the renin-angiotensin system in migraine","volume":"24","author":"Tronvik","year":"2006","journal-title":"J. Hypertens. Suppl."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24655_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11940-016-0397-2","article-title":"ACE and ARB agents in the prophylactic therapy of migraine-how effective are they?","volume":"18","author":"Halker","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24655_bib42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.10159","article-title":"Nuclear factor-kappaB as a molecular target for migraine therapy","volume":"51","author":"Reuter","year":"2002","journal-title":"Ann. Neurol."},{"issue":"22","key":"10.1016\/j.heliyon.2024.e24655_bib43","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e24655_bib44","article-title":"Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats","volume":"3","author":"Kojima","year":"2015","journal-title":"Phys. Rep."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24655_bib45","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3899\/jrheum.131210","article-title":"Scleroderma renal crisis","volume":"41","author":"Mouthon","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.heliyon.2024.e24655_bib46","series-title":"StatPearls","article-title":"Scleroderma and renal crisis","author":"Vaidya","year":"2022"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e24655_bib47","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrneph.2016.124","article-title":"Scleroderma renal crisis and renal involvement in systemic sclerosis","volume":"12","author":"Woodworth","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24655_bib48","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.1780260616","article-title":"Reversal of scleroderma renal crisis for more than two years in a patient treated with captopril","volume":"26","author":"Sorensen","year":"1983","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.heliyon.2024.e24655_bib49","first-page":"111","article-title":"Pharmacological treatment of scleroderma renal crisis: a systematic literature review","volume":"27","author":"de Zubir\u00eda-Maria","year":"2020","journal-title":"Rev. Colomb. Reumatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24655_bib50","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1524-6175.2003.01928.x","article-title":"Scleroderma renal crisis","volume":"5","author":"Prisant","year":"2003","journal-title":"J. Clin. Hypertens."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24655_bib51","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/diabetes.48.2.292","article-title":"Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting","volume":"48","author":"Ekberg","year":"1999","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24655_bib52","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-014-3451-1","article-title":"GLUT2, glucose sensing and glucose homeostasis","volume":"58","author":"Thorens","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.heliyon.2024.e24655_bib53","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/emm.2015.122","article-title":"Regulation of glucose metabolism from a liver-centric perspective","volume":"48","author":"Han","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.heliyon.2024.e24655_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2741\/1216","article-title":"Glucose transport in the heart","volume":"9","author":"Abel","year":"2004","journal-title":"Front. Biosci. : J. Vis. Literacy"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24655_bib55","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1172\/JCI7605","article-title":"Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart","volume":"104","author":"Abel","year":"1999","journal-title":"J. Clin. Invest."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e24655_bib56","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1161\/01.CIR.0000034049.61181.F3","article-title":"Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice","volume":"106","author":"Liao","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24655_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000301","article-title":"Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction","volume":"2","author":"Pereira","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.heliyon.2024.e24655_bib58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.yjmcc.2014.02.011","article-title":"GLUT1 deficiency in cardiomyocytes does not accelerate the transition from compensated hypertrophy to heart failure","volume":"72","author":"Pereira","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e24655_bib59","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1161\/01.CIR.103.24.2961","article-title":"Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis","volume":"103","author":"Tian","year":"2001","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24655_bib60","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","article-title":"Cardiac metabolism in heart failure: implications beyond ATP production","volume":"113","author":"Doenst","year":"2013","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24655_bib61","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0002-9343(90)90227-5","article-title":"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy","volume":"89","author":"Arauz-Pacheco","year":"1990","journal-title":"Am. J. Med."},{"issue":"8488","key":"10.1016\/j.heliyon.2024.e24655_bib62","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(86)91304-8","article-title":"Captopril, enalapril, and blood glucose","volume":"1","author":"McMurray","year":"1986","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24655_bib63","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jacc.2004.03.071","article-title":"Cardiovascular therapies and risk for development of diabetes","volume":"44","author":"Pepine","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24655_bib64","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3317\/jraas.2000.002","article-title":"The HOPE study (heart outcomes prevention evaluation)","volume":"1","author":"Sleight","year":"2000","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS"},{"issue":"5\u20136","key":"10.1016\/j.heliyon.2024.e24655_bib65","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/10641969909060984","article-title":"Recent intervention trials in hypertension initiated in Sweden--HOT, CAPPP and others. Hypertension optimal treatment study. Captopril prevention Project","volume":"21","author":"Hansson","year":"1999","journal-title":"Clin. Exp. Hypertens."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24655_bib66","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1262-3636(07)70146-5","article-title":"Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials","volume":"30","author":"Scheen","year":"2004","journal-title":"Diabetes Metab."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24655_bib67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/01.HYP.0000028979.98877.0C","article-title":"ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO","volume":"40","author":"Shiuchi","year":"2002","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24655_bib68","doi-asserted-by":"crossref","first-page":"E1204","DOI":"10.1152\/ajpendo.00281.2018","article-title":"Angiotensin-(1-7) contributes to insulin-sensitizing effects of angiotensin-converting enzyme inhibition in obese mice","volume":"315","author":"Loloi","year":"2018","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.heliyon.2024.e24655_bib69","first-page":"1","article-title":"Angiotensin converting enzyme inhibitor potentiates the hypoglycaemic effect of NG-nitro-L-arginine methyl ester (L-NAME) in rats","author":"Aluko","year":"2020","journal-title":"Arch. Physiol. Biochem."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e24655_bib70","first-page":"e5449","article-title":"Simple reason for hypoglycemia: ACE inhibitor-induced severe recurrent hypoglycemia in a nondiabetic patient","volume":"11","author":"Elshimy","year":"2019","journal-title":"Cureus"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e24655_bib71","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1056\/NEJM198909283211305","article-title":"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension","volume":"321","author":"Pollare","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24655_bib72","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/01.HYP.20.2.181","article-title":"Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension","volume":"20","author":"Santoro","year":"1992","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e24655_bib73","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.CIR.0000054611.89228.92","article-title":"Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24655_bib74","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0026-0495(96)90021-9","article-title":"Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle","volume":"45","author":"Jacob","year":"1996","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24655_bib75","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1677\/jme.0.0260155","article-title":"Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas","volume":"26","author":"Leung","year":"2001","journal-title":"J. Mol. Endocrinol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24655_bib76","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1530\/eje.0.1460567","article-title":"Regulation and expression of a renin-angiotensin system in human pancreas and pancreatic endocrine tumours","volume":"146","author":"Lam","year":"2002","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24655_bib77","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00125-003-1295-1","article-title":"Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets","volume":"47","author":"Lau","year":"2004","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24655_bib78","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2337\/diabetes.53.4.989","article-title":"Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat","volume":"53","author":"Tikellis","year":"2004","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24655_bib79","first-page":"77","article-title":"Lisinopril therapy associated with acute pancreatitis","volume":"163","author":"Marinella","year":"1995","journal-title":"West. J. Med."},{"issue":"1\u20133","key":"10.1016\/j.heliyon.2024.e24655_bib80","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0167-0115(02)00226-4","article-title":"Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis","volume":"111","author":"Tsang","year":"2003","journal-title":"Regul. Pept."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e24655_bib81","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2165\/00003495-200262090-00002","article-title":"The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications","volume":"62","author":"Bernobich","year":"2002","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24655_bib82","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00004872-199204001-00002","article-title":"Potassium as a link between insulin and the renin-angiotensin-aldosterone system","volume":"10","author":"Ferrannini","year":"1992","journal-title":"J. Hypertens. Suppl."},{"key":"10.1016\/j.heliyon.2024.e24655_bib83","series-title":"StatPearls","article-title":"Biochemistry, lipoprotein metabolism","author":"Lent-Schochet","year":"2021"},{"issue":"2 Pt 1","key":"10.1016\/j.heliyon.2024.e24655_bib84","first-page":"G164","article-title":"Intestinal triglycerides are derived from both endogenous and exogenous sources","volume":"248","author":"Shiau","year":"1985","journal-title":"Am. J. Physiol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24655_bib85","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cmet.2012.04.006","article-title":"Lipid metabolism and toxicity in the heart","volume":"15","author":"Goldberg","year":"2012","journal-title":"Cell Metabol."},{"issue":"Suppl 6","key":"10.1016\/j.heliyon.2024.e24655_bib86","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1097\/00005344-199306226-00016","article-title":"Serum lipoproteins during treatment with antihypertensive drugs","volume":"22","author":"Weidmann","year":"1993","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"6 Suppl 7","key":"10.1016\/j.heliyon.2024.e24655_bib87","first-page":"VII43","article-title":"The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis","volume":"13","author":"Chobanian","year":"1990","journal-title":"Clin. Cardiol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24655_bib88","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.jhh.1001315","article-title":"Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study","volume":"16","author":"Bakris","year":"2002","journal-title":"J. Hum. Hypertens."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24655_bib89","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.pharep.2015.01.008","article-title":"The effect of angiotensin-converting enzyme inhibition on inflammatory and angiogenic factors in hypercholesterolemia","volume":"67","author":"Mahmoudabady","year":"2015","journal-title":"Pharmacol. Rep."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e24655_bib90","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2174\/0929866524666170728153600","article-title":"Effects of resveratrol and ACE inhibitor enalapril on glucose and lipid profiles in mice","volume":"24","author":"de Almeida Pinheiro","year":"2017","journal-title":"Protein Pept. Lett."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e24655_bib91","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1703518","article-title":"ACE inhibitors and statins in adolescents with type 1 diabetes","volume":"377","author":"Marcovecchio","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24655_bib92","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0021-9150(99)00145-8","article-title":"Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis","volume":"146","author":"Keidar","year":"1999","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24655_bib93","article-title":"Angiotensin II induces cholesterol accumulation and injury in podocytes","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24655_bib94","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/pr.114.010454","article-title":"International union of basic and clinical pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli [corrected]","volume":"67","author":"Karnik","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24655_bib95","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.pcad.2015.11.004","article-title":"The divergent cardiovascular effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on myocardial infarction and death","volume":"58","author":"Strauss","year":"2016","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24655_bib96","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2125.1994.tb04240.x","article-title":"Effects of ACE inhibitors on oxidation of human low density lipoprotein","volume":"37","author":"Godfrey","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24655_bib97","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/MAJ.0b013e318224a147","article-title":"Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy","volume":"342","author":"Mitra","year":"2011","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.heliyon.2024.e24655_bib98","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40885-016-0060-y","article-title":"Comparison of endothelial function improvement estimated with reactive hyperemia index between ramipril and telmisartan in hypertensive patients","volume":"23","author":"Ki","year":"2017","journal-title":"Clin Hypertens"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24655_bib99","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5152\/TurkThoracJ.2018.18014","article-title":"Angiotensin-converting enzyme inhibitors induce cough","volume":"20","author":"Yilmaz","year":"2019","journal-title":"Turk Thorac J"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24655_bib100","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/08923973.2013.797992","article-title":"Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers","volume":"35","author":"Vena","year":"2013","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24655_bib101","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0897190017690641","article-title":"ACE inhibitor-induced angioedema of the small bowel: a case report and review of the literature","volume":"31","author":"Wilin","year":"2018","journal-title":"J. Pharm. Pract."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e24655_bib102","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.4155\/fmc-2018-0314","article-title":"Deep learning and virtual drug screening","volume":"10","author":"Carpenter","year":"2018","journal-title":"Future Med. Chem."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e24655_bib103","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10822-005-9017-z","article-title":"Validated ligand mapping of ACE active site","volume":"19","author":"Kuster","year":"2005","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24655_bib104","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF01680553","article-title":"A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies","volume":"1","author":"Mayer","year":"1987","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e24655_bib105","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.drudis.2014.06.026","article-title":"How to design a potent, specific, and stable angiotensin-converting enzyme inhibitor","volume":"19","author":"Regulska","year":"2014","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24655_bib106","article-title":"New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human","volume":"9","author":"Fagyas","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24655_bib107","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/01.HYP.1.3.281","article-title":"Inhibition of human peptidyl dipeptidase (angiotensin I converting enzyme: kininase II) by human serum albumin and its fragments","volume":"1","author":"Klauser","year":"1979","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24655_bib108","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.844","article-title":"Benefits and adverse effects of sacubitril\/valsartan in patients with chronic heart failure: a systematic review and meta-analysis","volume":"9","author":"Charuel","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24655_bib109","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/clc.23744","article-title":"Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: the PERI-STEMI study","volume":"44","author":"Diao","year":"2021","journal-title":"Clin. Cardiol."},{"issue":"52","key":"10.1016\/j.heliyon.2024.e24655_bib110","article-title":"Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: a PRISMA-compliant article","volume":"100","author":"Lin","year":"2021","journal-title":"Medicine (Baltim.)"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24655_bib111","article-title":"Sacubitril\/valsartan in heart failure hospitalization: two pills a day to keep hospitalizations away?","volume":"15","author":"Sakhamuri","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.heliyon.2024.e24655_bib112","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024006868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024006868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:37:50Z","timestamp":1783931870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024006868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844024006868"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24655","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACE inhibitors and their interaction with systems and molecules involved in metabolism","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e24655"}}